An Overview of Systematic Reviews of Using Chinese Medicine to Treat Polycystic Ovary Syndrome

Table 9

GRADE quality-of-evidence ratings for follicle-stimulating hormone level.

Included systematic reviews	Number of studies included	Follicle-stimulating hormone effect (95% CI)	GRADE quality of evidence	Relegation factors
Ji Lin 2019 [26]	19	SMD = 0.12, 95% CI (–0.29, –0.53)	Very low	①②④
Xie Peng Peng et al 2019 [27]	11	WMD = –0.59, 95% CI (–0.98, –0.20)	Very low	①②④
ZhongYizheng et al. 2019 [28]	8	SMD = 0.66, 95% CI (0.51, 0.82)	Low	①④
Dong YuFang 2020 [29]	37	SMD = 0.01, 95% CI (–0.22, 0.25)	Very low	①②④⑤
Li Nan et al. 2020 [30]	5	SMD = –1.67, 95% CI (–3.05, –0.30)	Very low	①②④⑤
Chen JinMing et al. 2020 [33]	2	MD = 0.13, 95% CI (–0.39, 0.66)	Very low	①②④⑤

Note. CI: confidence interval; MD: mean difference; SMD: standardized mean difference; WM: weighted mean difference; ①: limitation; ②: inconsistency; ③: indirectness; ④: publication bias; ⑤: imprecision.